A Phase 1 Study of INCB123667 in People With Advanced Gynecologic Cancers


Full Title

A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors


In this study, researchers are assessing the drug INCB123667 in people with advanced gynecologic cancers whose tumors keep growing. The people in this study have ovarian, fallopian tube, peritoneal, endometrial, or uterine cancer. Their tumors make too much of a protein called cyclin E1 or has too many copies of the CCNE1 gene.

INCB123667 blocks a protein called CDK2 that plays a role in the growth and survival of cancer cells. By blocking this protein, INCB123667 may slow or stop the growth of your cancer. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have an advanced gynecologic cancer that keeps growing.
  • Have recovered from the serious side effects of prior therapies.
  • May not have had previous treatment with a CDK2 inhibitor.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Chrisann Kyi’s office at 646-888-4221.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID